Bremelanotide (Vyleesi): FDA-Approved Use, Evidence, and What It Actually Does

Most peptides discussed online have thin human evidence. Bremelanotide is an exception. It is the active ingredient in Vyleesi, a product the U.S. Food and Drug Administration approved in June 2019. That makes it one of the few peptides in the broader "research peptide" conversation that actually cleared a full new drug application, with phase 3 trials, a published label, and defined safety language.

Side effects get their own companion guide on PT-141 side effects and safety. The focus here is narrower: what bremelanotide actually is, how it is thought to work, what the approving evidence showed, and where the legitimate claim ends. Knowing the approved frame is the best defense against marketing that stretches a real medicine past what it earned.

Evidence Snapshot

What Bremelanotide Is

Bremelanotide is a synthetic cyclic heptapeptide — a small, seven-amino-acid ring with a free acid at one end and an acetylated amino group at the other. It is a melanocortin receptor agonist, derived from the same broad family of research that produced Melanotan II. In its development years it was widely known by the research code PT-141, which is why the two names appear together online. They refer to the same molecule.

The key distinction is regulatory, not chemical. Vyleesi is a finished, sealed autoinjector product with controlled manufacturing, a fixed concentration, defined excipients, and stability testing behind it. "PT-141" sold as a loose vial is not that product, even if the underlying peptide sequence is the same. The approved evidence base belongs to the reviewed product, not to anything that borrows the name.

How It Is Thought To Work

Bremelanotide acts on melanocortin receptors, with the most relevant target being the melanocortin-4 receptor (MC4R) in the central nervous system. It also has activity at MC1R and MC3R, but its potency is roughly an order of magnitude higher at MC4R than MC3R and about a hundredfold higher at MC4R than MC1R. That MC4R activity in the brain is the mechanism tied to its approved effect on sexual desire.

This is a genuinely different mechanism from the better-known drugs in this space. Sildenafil and similar agents are PDE5 inhibitors that increase genital blood flow. Bremelanotide is neither a PDE5 inhibitor nor a hormone. It works centrally, on neural circuits, rather than on the vasculature. Its non-MC4R activity also explains parts of its safety profile: MC1R signaling is linked to pigmentation, and MC4R activation can produce transient blood-pressure increases and heart-rate decreases.

The Approved Use Is Specific

Vyleesi is approved for one thing: acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Each word in that phrase narrows the population. "Acquired" means the low desire is a change from a previous baseline, not lifelong. "Generalized" means it is not limited to a specific partner or situation. And HSDD requires that the low desire causes marked personal distress or interpersonal difficulty and is not primarily explained by another medical or psychiatric condition, relationship problems, or a substance or medication.

None of that supports the way the molecule is often marketed. The approval does not cover men, does not cover postmenopausal women, and does not endorse bremelanotide as a general arousal or sexual-performance enhancer. When a source presents PT-141 as a unisex libido booster, it is reaching well past the studied indication.

What The Trials Actually Showed

The approval rested on two identical phase 3 randomized, double-blind, placebo-controlled trials known as RECONNECT, which together enrolled 1,247 premenopausal women with acquired, generalized HSDD over 24 weeks. Participants used as-needed subcutaneous bremelanotide 1.75 mg. The coprimary endpoints were change in a desire-domain score and change in a distress item related to low desire.

The result was a real but modest signal. Roughly a quarter of women on bremelanotide reached a meaningful improvement in desire score, versus about 17 percent on placebo, and about 35 percent had a one-point or greater drop in distress, versus about 31 percent on placebo. Crucially, the number of satisfying sexual events did not differ significantly from placebo. That nuance is routinely lost online: bremelanotide improved how women rated their desire and distress, not a tally of sexual encounters. A longer open-label extension supported tolerability over time without overturning that core picture.

Brain-Imaging Evidence For The Mechanism

A 2022 study in the Journal of Clinical Investigation used functional MRI to look at how MC4R agonism changes brain processing of erotic stimuli in women with HSDD. It reported that bremelanotide enhanced activity in some regions while reducing activity in the secondary somatosensory cortex, and increased connectivity between the amygdala and insula. The authors interpreted this as the drug reducing excessive self-monitoring and top-down inhibition of sexual response.

Imaging like this offers a plausible biological story for the desire effect rather than leaning on questionnaires alone. Read it carefully, though. Mechanistic imaging supports a hypothesis about how the drug acts; it does not prove a large clinical benefit. The phase 3 endpoints remain the measure of how much it helped.

Where The Legitimate Claim Ends

Bremelanotide is a real, approved, centrally acting peptide medicine with a modest, well-defined benefit in a narrow population. That is exactly why claims beyond that frame deserve scrutiny. An FDA-reviewed label for premenopausal HSDD does not validate a research-market vial, does not extend to men or postmenopausal women, and does not turn the drug into a recreational enhancer.

The product-identity issue is the same one we flag across the site in Approved vs Investigational vs Compounded vs Research Peptides and GLP-1 Drugs vs Other Peptides. A familiar ingredient name does not make every vial equal to the studied drug. Our reconstitution calculator can do the math, but arithmetic cannot confirm what is in an unapproved product.

Reader Checklist

When you read a bremelanotide or PT-141 claim, ask:

• Is the source talking about FDA-approved Vyleesi, or a research-market vial labeled PT-141?
• Is the claim about premenopausal women with acquired, generalized HSDD, or is it stretched to other populations?
• Does it acknowledge that the benefit was modest, and that satisfying sexual events did not significantly differ from placebo?
• Does it describe the central MC4R mechanism, rather than implying a blood-flow or testosterone effect?
• Does it separate bremelanotide from Melanotan II instead of merging all melanocortin peptides?
• Does it stop short of turning trial data into dosing or sourcing advice for an unapproved vial?

Bremelanotide earns more credibility than most peptides precisely because it went through the full approval process. The same fact sets its limits: the real evidence is specific, the benefit is modest, and everything outside the label is a separate, weaker question.

FAQ

Is bremelanotide FDA approved?

Yes. Bremelanotide is the active ingredient in Vyleesi, approved by the FDA in 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. That approval is specific to that indication and population.

How is bremelanotide different from Viagra?

Sildenafil (Viagra) is a PDE5 inhibitor that affects genital blood flow. Bremelanotide is a melanocortin-4 receptor agonist that acts on brain pathways involved in sexual desire. They target different problems through different mechanisms.

Does this article tell me how to use bremelanotide?

No. It explains what bremelanotide is, how it works, and what the approved-use evidence shows. It does not provide dosing, sourcing, or treatment advice. Those decisions belong with a qualified clinician using the approved label.

References

• VYLEESI (bremelanotide injection) full prescribing information, U.S. Food and Drug Administration.
• NDA 210557 approval letter for Vyleesi, U.S. Food and Drug Administration.
• FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women, Palatin Technologies / PR Newswire.
• Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials, Obstetrics & Gynecology / PubMed.
• Melanocortin 4 receptor agonism enhances sexual brain processing in women with HSDD, Journal of Clinical Investigation, 2022.
• Bremelanotide for Treatment of Female Hypoactive Sexual Desire, Neurology International / PMC.
• Bremelanotide — LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, NCBI Bookshelf / NIDDK.
• PT-141 Side Effects and Safety: What Bremelanotide Evidence Actually Shows, Peptides Defined.

Disclaimer

This page is educational and is not medical advice. It does not provide dosing, reconstitution, injection, compounding, sourcing, purchase, or treatment instructions for bremelanotide or PT-141. Treatment decisions should be made with a qualified healthcare professional using the approved product label, personal medical history, and appropriate monitoring.